Organon & (OGN) revenue breakdown
By product, Nexplanon/Implanon NXT is the largest at 15% of fiscal 2025 revenue; Other grew fastest, 6% a year over 6 years.
By region, Europe and Canada is the largest at 26% of fiscal 2025 revenue; Latin America, Middle East, Russia, and Africa grew fastest, 3% a year over 6 years.
Revenue by product
Fiscal years, as Organon & reports them in its 10-K filings; fiscal 2025 total $6.2B.
| Products | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|
| Nexplanon/Implanon NXT | $787M | $680M | $769M | $834M | $830M | $963M | $921M | 15% |
| Zetia | $590M | $482M | $378M | $370M | $322M | $317M | $342M | 6% |
| Other | $238M | $379M | $357M | $326M | $319M | $328M | $338M | 5% |
| Atozet | $391M | $453M | $458M | $457M | $519M | $473M | $324M | 5% |
| Other Non-Opiod Pain, Bone and Dermatology | $214M | $278M | $286M | $273M | $275M | $295M | $301M | 5% |
| Arcoxia | $288M | $258M | $244M | $241M | $257M | $270M | $265M | 4% |
| Follistim AQ | $241M | $193M | $237M | $229M | $262M | $237M | $264M | 4% |
| Nasonex | $293M | $218M | $206M | $260M | $266M | $276M | $262M | 4% |
| Singulair | $698M | $462M | $413M | $411M | $404M | $359M | $252M | 4% |
| Renflexis | $96M | $135M | $186M | $226M | $278M | $274M | $251M | 4% |
| Hadlima | — | — | $13M | $19M | $44M | $142M | $228M | 4% |
| Cozaar/Hyzaar | $442M | $386M | $357M | $323M | $281M | $243M | $219M | 4% |
| Emgality | — | — | — | — | — | $107M | $174M | 3% |
| Other Women's Health | $173M | $270M | $206M | $138M | $147M | $158M | $174M | 3% |
| Dulera | $217M | $222M | $190M | $180M | $194M | $203M | $153M | 2% |
| Diprospan | $102M | $118M | $125M | $122M | $91M | $139M | $150M | 2% |
| Fosamax | $197M | $180M | $175M | $152M | $159M | $151M | $143M | 2% |
| Vtama | — | — | — | — | — | $12M | $128M | 2% |
| Marvelon/Mercilon | — | $95M | $98M | $110M | $134M | $134M | $127M | 2% |
| Other Cardiovascular | $134M | $239M | $191M | $146M | $139M | $133M | $126M | 2% |
| Clarinex | $142M | $130M | $111M | $125M | $136M | $127M | $123M | 2% |
| Propecia | $131M | $129M | $136M | $125M | $125M | $111M | $118M | 2% |
| Ganirelix Acetate Injection | $112M | $81M | $111M | $123M | $110M | $109M | $101M | 2% |
| Vytorin | $285M | $182M | $164M | $130M | $129M | $108M | $100M | 2% |
| Ontruzant | $83M | $115M | $126M | $122M | $155M | $141M | $99M | 2% |
| Proscar | $203M | $176M | $117M | $101M | $97M | $95M | $97M | 2% |
| NuvaRing | $879M | $236M | $191M | $219M | $176M | $115M | $91M | 1% |
| Other | $102M | $107M | $200M | $146M | $121M | $115M | $82M | 1% |
| Brenzys | $72M | $74M | $63M | $75M | $73M | $77M | $80M | 1% |
| Jada | — | — | $3M | $20M | $43M | $61M | $74M | 1% |
| Other Respiratory | $25M | $118M | $89M | $61M | $64M | $53M | $52M | 1% |
| Other Biosimilars | — | $6M | $36M | $39M | $43M | $28M | $33M | 1% |
| Rosuzet | $120M | $130M | $68M | $71M | $70M | $49M | $24M | 0% |
| Zocor | $112M | — | — | — | — | — | — | — |
| Asmanex | $94M | — | — | — | — | — | — | — |
| Diprosone | $84M | — | — | — | — | — | — | — |
| Remeron | $82M | — | — | — | — | — | — | — |
| Sinemet | $79M | — | — | — | — | — | — | — |
| Cerazette | $71M | — | — | — | — | — | — | — |
Revenue by region
Fiscal years, as Organon & reports them in its 10-K filings; fiscal 2025 total $6.2B.
| Regions | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|
| Europe and Canada | $1.9B | $1.7B | $1.7B | $1.6B | $1.7B | $1.8B | $1.6B | 26% |
| U.S. | $2.0B | $1.4B | $1.4B | $1.4B | $1.5B | $1.6B | $1.6B | 26% |
| Latin America, Middle East, Russia, and Africa | $923M | $857M | $841M | $895M | $965M | $1.0B | $1.1B | 17% |
| Asia Pacific and Japan | $1.8B | $1.5B | $1.2B | $1.1B | $1.1B | $1.1B | $1.0B | 16% |
| China | $1.0B | $873M | $933M | $917M | $864M | $847M | $829M | 13% |
| Other | $124M | $133M | $233M | $151M | $154M | $137M | $93M | 1% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for OGN.
Open OGN in InvestinglyQuestions
Where does Organon & make its money?
In fiscal 2025, by product: Nexplanon/Implanon NXT $921M, Zetia $342M, Other $338M, Atozet $324M, Other Non-Opiod Pain, Bone and Dermatology $301M.
From Organon &'s annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.